



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

SD-169

Cat. No.:	HY-W015445
CAS No.:	1670-87-7
Molecular Formula:	C ₉ H ₈ N ₂ O
Molecular Weight:	160.18
Target:	p38 MAPK
Pathway:	MAPK/ERK Pathway
Storage:	4°C, protect from light
	* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (624.30 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		6.2430 mL	31.2149 mL	62.4298 mL
		5 mM		1.2486 mL	6.2430 mL	12.4860 mL
		10 mM		0.6243 mL	3.1215 mL	6.2430 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (12.99 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (12.99 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil					
	Solubility: ≥ 2.08 mg/mL (12.99 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC ₅₀ of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC ₅₀ of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation ^[1] .	
IC ₅₀ & Target	p38α MAPK 3.2 nM (IC ₅₀)	p38β MAPK 122 nM (IC ₅₀)
In Vitro	SD-169 significantly reduces p38 and HSP60 expression in T cells of the pancreatic beta islets ^[1] . SD-169 demonstrates 38-fold potency against p38α MAP kinase (IC ₅₀ =3.2 nM) than p38β MAP kinase (IC ₅₀ =122 nM) ^[1] .	

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Medicherla S, et al. Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes. J Pharmacol Exp Ther. 2006 Jul;318(1):99-107.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA